Shanghai Junshi Biosciences Co (HKSE:01877) Debt-to-EBITDA : -2.56 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shanghai Junshi Biosciences Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$1,344.3 Mil. Shanghai Junshi Biosciences Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$1,819.0 Mil. Shanghai Junshi Biosciences Co's annualized EBITDA for the quarter that ended in Mar. 2024 was HK$-1,237.8 Mil. Shanghai Junshi Biosciences Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -2.56.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:01877' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.5 Med: -0.83 Max: -0.56
Current: -2.5

During the past 8 years, the highest Debt-to-EBITDA Ratio of Shanghai Junshi Biosciences Co was -0.56. The lowest was -2.50. And the median was -0.83.

HKSE:01877's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs HKSE:01877: -2.50

Shanghai Junshi Biosciences Co Debt-to-EBITDA Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Debt-to-EBITDA Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-1.25

-0.57

-2.04

-0.56

-0.83

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial														-	-0.66	-	N/A	-2.56

Competitive Comparison of Shanghai Junshi Biosciences Co's Debt-to-EBITDA

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Debt-to-EBITDA falls into.

Shanghai Junshi Biosciences Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shanghai Junshi Biosciences Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(629.275	+	1327.022)	/	-2360.004
	=	-0.83

Shanghai Junshi Biosciences Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1344.306	+	1818.968)	/	-1237.796
	=	-2.56

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Shanghai Junshi Biosciences Co (HKSE:01877) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Shanghai Junshi Biosciences Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines